This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

DETECTION, INCIDENCE, PROGNOSTIC SIGNIFICANCE AND RELATION TO THERAPIES

JESSE G. M. BULLOWA, M.D.; PAUL F. de GARA, M.D.; SAMUEL C. BUKANTZ, M.D.

Arch Intern Med. 1942;69(1):1-14.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Because it was thought that a study of the demonstrable phenomena of immunity of the host which accompany recovery from pneumococcic infections provided an approach to rational therapeutic procedure, such phenomena were the chief concern of investigators prior to the introduction of sulfapyridine (2-[paraaminobenzenesulfonamido]-pyridine). Ever since the drug has been therapeutically employed attention has shifted to the infecting organism and emphasis has been placed on the mechanism of bacteriostasis. At present, attention is again directed to the humoral recovery mechanisms in relation to the action of sulfanilamide and its derivatives. Whitby found that sulfapyridine did not affect the quality, quantity or speed of production of antibodies. It has been observed that many patients who recover from pneumococcic pneumonia under treatment with sulfapyridine do so without any detectable circulating antibodies having developed. Results of adequate investigation of the possible complementary activity of the drug and of the antibody have not been . . . [Full Text PDF of this Article]

Author Affiliations
Clinical Professor of Medicine, New York University College of Medicine, and Visiting Physician, Harlem Hospital; NEW YORK

From the medical service, Harlem Hospital, the Department of Hospitals of New York City, and the Littauer Pneumonia Research Fund of New York University College of Medicine.

Footnotes
Dazian Fellow.

Littauer Fellow in Pneumonia Research.

This study received additional financial support from the Metropolitan Life Insurance Company and from Mr. Bernard M. Baruch, Mr. Bernard M. Baruch Jr., Miss Belle N. Baruch and Mrs. Robert H. Samstag.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?